•
RM
RMD
ResMed Inc.
yahooSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
--
Price Chart
Market Cap
37.85B
Volume
550.04K
52W High
$293.81
52W Low
$199.92
Open
$0.00
Prev Close
$253.19
Day Range
0.00 - 0.00
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Latest News
Global Sleep Apnea Devices Market is Expected to Cross the USD 15 Billion Mark by 2032 | DelveInsight
GlobeNewswire Inc.•15h ago
BVI Appoints Jim Hollingshead as President & Chief Executive Officer
GlobeNewswire Inc.•Jan 19
Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight
GlobeNewswire Inc.•Jan 6
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
GlobeNewswire Inc.•Nov 14
Saudi Arabia $5.94 Bn Sleep Apnea Devices Market Trends, Competition, Forecast & Opportunities, 2030F Featuring ResMed, Philips, Invacare, Itamar Medical, and Nihon Kohden
GlobeNewswire Inc.•Oct 7
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research®
GlobeNewswire Inc.•Jul 21
Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
GlobeNewswire Inc.•May 28
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
Benzinga•Apr 24